NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,418+0.42%BTC$81,092+6.14%VIX14.81−4.08%live tape · as of 21:00 UTC
The Screen · Healthcare · Biotechnology
Bio-Techne
TECH · a US exchange · USD · Market cap $11.3B · 3,100 employees
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Screened 2026-09-10 · the tape above runs as of 21:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Bio-Techne holds its Accumulation at $72.08. Elevated stress, defensive posture warranted, held for 13 days.
As held on the ledger · 2026-09-10
Phase
Accumulation
Quantitative state
Elevated stress, defensive posture warranted, held for 13 days
Price at the screen
$72.08
Valuation
62.14 trailing · 31.25 forward price to earnings
Values screen
PASS· score 85.3
Beta
1.28
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
17.36%
Below 33%
Interest-bearing debt is just 17.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
9.81%
Below 33%
Cash held in interest-bearing accounts and securities is 9.8% of assets, under the one-third limit.
Pass
Receivables
14.43%
Below 49%
Money owed to the company is 14.4% of assets, under the 49% limit.
Pass
Revenue purity
0.32%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades above our $61.87 fair value estimate, narrow competitive moat, 1.30% revenue growth.
Fair value range in USD, drawn from the 2026-09-10 screen. The gold marker is the market price at the same screen. The price runs 14.2% above the base estimate.
Third-party analyst targets: 11 covering, consensus Hold. The average target sits +1% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-10 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Lab tools priced far above their growth
Picture a supplier to drug researchers whose sales are shrinking yet still trades at a 35 times forward earnings multiple. Bio-Techne sits there right now, with revenue down 2 percent, a 9 percent profit margin and just 5 percent return on equity. Our fair value sits at 59 dollars against the current 72 dollar price, leaving an 18 percent negative margin of safety and an overvalued call.
The narrow moat and hold rating from twelve analysts at a 73 dollar median target do not change the arithmetic. Ethical screens clear, yet the valuation leaves no room for the flat or falling top line the numbers already show.
Cyclical demand in research budgets can turn quickly, and a narrow moat offers little protection when growth stays negative. The gap between price and fair value remains the clearest signal.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TECH trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-14Markdown · changed$72.08+0.3%Entry 5
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 38.3% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61.
2026-07-18Distribution$51.99+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $61.
2026-07-03Distribution$51.99+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$51.99Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.